Cancer Patients Face Drug Access Challenges Amid VAT Dispute

Bayer has halted the acceptance of new patients into its early access scheme, amidst an ongoing dispute with HMRC regarding tax liabilities on free-of-charge medicines. This decision has raised concerns within the UK pharmaceutical industry, with implications for patients suffering from life-threatening conditions.

The early access scheme was designed to provide patients with medicines that have not yet received marketing authorisation or NHS funding. These treatments are vital for individuals with severe or chronic illnesses that cannot be adequately managed by existing licensed medications.

A letter from Julia Lopez, shadow secretary for science, innovation and technology, has brought further attention to the issue. She conveyed that pharmaceutical companies cannot absorb the VAT bills imposed for supplying these essential drugs free of charge. This taxation change could jeopardise the UK’s reputation as a leader in clinical research.

A Bayer spokesperson confirmed that the company previously supplied treatments to patients categorised under serious conditions. However, due to the recent tax changes, they made the difficult choice to pause the addition of new patients while continuing to support those already enrolled.

The UK’s Department for Science, Innovation and Technology has acknowledged the complexities surrounding VAT regulations. The application of these rules can vary based on the particulars of each supply, including whether the goods are provided for free.

Concerns persist that the tax policy may deter pharmaceutical firms from operating within the UK, especially in relation to compassionate use and early access schemes. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, emphasised that these policies could limit NHS patients’ access to critical medications.

Government representatives have engaged in discussions with the pharmaceutical sector. They have expressed a commitment to maintaining access to early access and compassionate use schemes, recognising their significance for patient care.